http://www.assamtribune.com/scripts/detailsnew.asp?id=mar1717/city051
............................................................................................................. this blog is started in a simple attempt to discuss and spread knowlege regarding respiratory, critical care and sleep medicine related disorders ....this will bring doctors together in same plateform .....................................
Search This Blog
Pages
translate
Saturday, March 18, 2017
world sleep day celebration in guwahati 2017
http://www.assamtribune.com/scripts/detailsnew.asp?id=mar1717/city051
Sunday, February 26, 2017
ACLS Guide to the Human Respiratory System
https://pacificmedicalacls.com/acls-guide-to-the-human-respiratory-system.html
Wednesday, August 24, 2016
MANAGEMENT OF COPD & ASTHMA - CERTIFIED COURSE
Sunday, July 10, 2016
HOW TO HAVE A GOOD NIGHT SLEEP .....................
Friday, May 20, 2016
Tuesday, February 2, 2016
THORACIC ULTRSONOGRAPGY- FOR PULMONOLOGIST
Saturday, August 15, 2015
NATIONAL SLEEP MEDICINE COURSE 2015 www.nsmc2015.in
NATIONAL SLEEP MEDICINE COURSE 2015 GUWAHATI 5th and 6th december
IT IS COMPREHENSIVE COURSE BY INDIAN SOCIETY FOR SLEEP RESEARCH
for details visit www.nsmc2015.in
5 international faculties and national faculties will be present during this two day course
Sunday, June 15, 2014
sleep apnea in children
clinical picture is different from adult
they may present with poor school performance, bed wetting, attention deficit hyperactivity disorder.
Has a strong co-realtion with childhood obesity
Diagnosis
by overnight polysomnography
Friday, May 9, 2014
BLACK DAY IN HISTORY OF MEDICAL SCIENCE OF ASSAM
Saturday, April 12, 2014
oxygen therapy

Organ specific
sign and symptoms of hypoxia
|
|
System
|
Sign
and symptoms
|
Respiratory
|
Tachypnea, breathlessness,
dyspnea, cyanosis
|
cardiovascular
|
Increased cardiac
output, palpitations, tachycardia, arrhythmias, hypotension, angina,
vasodilatation, diaphoresis, and shock
|
CNS
|
Headache, impaired
judgment, inappropriate behavior, confusion, euphoria, delierium,
restlessness, papilledema, seizures, obtundation, coma
|
neuromuscular
|
Weakness, tremor,
asterixis,
hyper-reflexia, incoordination
|
metabolic
|
Sodium and water
retention, lactic acidosis
|
Mechanism
|
Clinical conditions
|
Diagnostic criteria
|
General treatment
|
Response to oxygen
therapy
|
Low FiO2
|
High altitude, fire,
smoke
|
History, low
atmospheric pressure of oxygen
|
Supportive care
|
Rapid
|
Hypoventilation
|
Neuromuscular disease,
CNS depression, narcotics
|
Increase in PaCO2
similar to decrease in PaO2
|
ventilator care
(invasive/non invasive)
|
Good initial response
|
V/Q mismatch
|
COPD
|
Increase PAO2-PaO2,
corrected by 100% O2
|
Bronchodilator,
bronchial hygine
|
Moderately rapid
|
Right to left shunt
|
Pneumonia, collapse,
pulmonary edema
|
Not corrected by 100%
O2
|
Antibiotics,
diuretics, PEEP
|
variable
|
Diffusion defect
|
Interstitial lung
diseases
|
Low vital capacity,
low diffusion capacity
|
Corticosteroids,
immunosupresant etc
|
Moderately rapid
|
Clinical conditions (grade of recommendations)
|
Comment
|
|
Critical illnesses requiring high levels of supplemental oxygen
|
Cardiac arrest or resuscitation(Grade D)
Shock, sepsis, major trauma,
near-drowning, anaphylaxis,
major pulmonary haemorrhage(Grade D)
Major head injury(Grade D)
Carbon monoxide poisoning(Grade C)
|
|
Serious illnesses requiring moderate levels of supplemental oxygen if
the patient is hypoxaemic
|
Acute hypoxaemia
(cause not yet diagnosed) (Grade D)
Acute asthma (Grade C)
Pneumonia ( Grade C)
Lung cancer (Grade C)
Postoperative breathlessness (Grade D)
Acute heart failure (Grade D)
Pulmonary embolism (Grade D)
Pleural effusions (Grade D)
Pneumothorax (Grade C & D)
Deterioration of lung fibrosis
or other interstitial lung
disease (Grade D)
Severe anaemia Grade B & D)
Sickle cell crisis (Grade B)
|
The initial oxygen therapy is nasal cannulae at 2–6 l/min (preferably)
or simple face mask at 5–10 l/min unless stated otherwise.
|
conditions requiring controlled or low-dose oxygen therapy
|
COPD(Grade C)
Exacerbation of CF(Grade D)
Chronic neuromuscular
Disorders(Grade D)
Chest wall disorders(Grade D)
Morbid obesity (Grade D)
|
60 min [Grade D]
|
Conditions for which patients should be monitored closely but oxygen
therapy is not required unless the patient is
hypoxaemic
|
Myocardial infarction and acute
coronary syndromes(Grade D)
Stroke (Grade B)
Pregnancy and obstetric
Emergencies (Grade A- D)
Hyperventilation or dysfunctional
Breathing (Grade C)
Most poisonings and drug
Overdoses (Grade D)
Poisoning with paraquat or
Bleomycin (Grade C)
Metabolic and renal disorders (Grade D)
Acute and subacute neurological
and muscular conditions
producing muscle weakness (Grade C)
|
|
- A definitive documented diagnosis of chronic hypoxemia (3 week apart)
- Patient is on optical medical management and stable
- Oxygen administration should have been shown to improve hypoxemia and provide clinical benefit
- At rest, in non recumbent position, the PaO2 of 55 mm Hg or less
- Patient with PaO2 between 55 to 60 mm Hg is considered for LTOT if-
- Patient on optimal medical treatment with demonstrable hypoxic organ dysfunction like secondary pulmonary arterial hypertension, cor pulmonale, polycythemia or CNS dysfunction
- When there is demonstrable fall in PaO2 < 55 mm Hg during sleep, associated with disturbed sleep pattern, cardiac arrhythmias or pulmonary hypertension. These patient may be benefited from nocturnal oxygen therapy.
- When there is demonstrable fall in PaO2 during exercise and oxygen administration is shown to improve exercise performance, duration or capacity. These patient may be benefited from oxygen therapy during exercise.
- Rebreathing systems
- Have a CO2 absorber
- Used in anaesthesia
- Non-rebreathing systems
Low flow system
|
High flow system
|
Nasal cannula and catheters
Facemasks
-Simple facemask
-Reservoir masks
-Partial rebreather
-Non rebreathers
Endotracheal and tracheostomy tubes with T Piece
|
Venturi masks
Non rebreathing reservoir mask with blending device
and high flow meters
Endotracheal and tracheostomy tubes with mechanical
ventilation
|
FiO2 depends upon:
•
Size of available oxygen reservoir
•
Flow rate
•
Breathing pattern (VT and RR)
|
FiO2 depends on:
•
velocity of the jet (the size of orifice and oxygen flow rate)
•
size of the valve ports
High flow systems deliver about 40 l/min of gas
through the mask, which is usually sufficient to meet the total respiratory
demand
This ensures that the breathing pattern will not
affect the FiO2
|
Patient in respiratory distress
|
Stable patient
|
|
Ventilatory
minute volume
(Respiratory
rate x
tidal volume)
|
30 l/min
(40 breaths/min x
750 ml/breath)
|
5 l/min
(10 breaths/min x
500 ml/breath)
|
Oxygen
flow rate
|
2L/min
|
2L/min
|
Calculation
of inspired
oxygen
concentration
(FiO2)
|
2 l/min of 100% oxygen
+
28 l/min of air drawn into the
mask (21% oxygen)
=
30 l/min minute volume
Thus
FiO2 =
(1.0x2) + (0.21x28) /30
= 0.26 (26%)
|
2 l/min of 100% oxygen
+
3 l/min of air drawn into the
mask (21% oxygen)
=
5 l/min minute volume
Thus
FiO2 =
(1.0x2) + (0.21x3)/
5= 0.53 (53%)
|
Delivery devices
|
Oxygen flow(lit/min)
|
FiO2
|
Nasal cannula
|
1
2
3
4
5
6
|
24%
28%
32%
36%
40%
44%
|
Simple face mask
|
6-10
|
40-60%
|
Reservoir mask
|
6-10
|
40-60%
|
Partial rebreathing
|
8-10
|
35-80%
|
Non rebreahting
|
8-10
|
40-100%
|
- Blood substitutes-
- Hemoglobin based oxygen carriers (HBOC)-
- Perfluorocarbon based oxygen carriers-
- Extracorporeal membrane oxygenation (ECMO)-
- Heliox therapy-
Pulse oxymetry
|
recommendation
|
SpO2 >95%
|
Oxygen not required
|
SpO2 92-95% without
risk factors
|
Oxygen not required
|
SpO2 92-95% with risk
factors (eg COPD, asthma, previous venous thromboembolism etc)
|
Hypoxic challenge
test
|
SpO2 <92%
|
In flight oxygen
|
After Hypoxic challenge test
|
|
Blood gas report
|
recommendation
|
PaO2 >55 mmHg
|
Oxygen not required
|
PaO2 50-55 mmHg
|
borderline
|
PaO2 <50 mmHg
|
In flight oxyen
|
- Suppression of hypoxic ventilator drive seen patient with chronic hypoxemia and hypercapnea whose ventilator drive is primarily driven by hypoxia (eg COPD). This can be prevented by controlled oxygen delivery.
- Absorption atelectasis seen in patient receiving very high FiO2.
- FiO2 >80% cause mild increase in peripheral vascular resistance and mild decrease in cardiac output.
- Inhalation of 100% FiO2 causes about 10% decrease in minute ventilation and decrease in diffusion capacity.
Pulmonary Changes
during Hyperoxic Exposure in Humans
|
||
O2 at 1 atm
|
Duration of exposure
|
Pathophysiological
changes
|
100%
|
>12 h
|
Decreased
tracheobronchial clearance; decreased forced vital capacity; cough; chestpain
|
>24hr
|
Altered endothelial
function
|
|
>36hr
|
Increased
alveolar-arterial oxygen gradient; decreased carbon monoxide diffusing
capacity
|
|
>48hr
|
Increasing alveolar
permeability; pulmonary
edema; surfactant
inactivation
|
|
>60hr
|
Acute respiratory
distress syndrome
|
|
60%
|
7 days
|
Mild chest
discomfort without changes in lung
mechanics; possible
changes in morphometry
|
24-28%
|
months
|
Subclinical
pathological changes; no clinical toxicity
documented
|
Bibliography
1. D F Treacher, R M Leach. Oxygen transport—1. Basic principles BMJ 1998;317:1302-1306
- Jindal Sk, Agarwal R Oxygen therapy 2nd edition 2008 Jaypee
- N T Bateman, R M Leach. Acute oxygen therapy: BMJ 1998;317:798801
- BTS guideline for emergency oxygen use in adult patients. Thorax 2008;63(Suppl VI):vi1–vi68.
- Warrel DA, Edwards RHT, Godfrey S, et al. Effect of controlled oxygen therapy onarterial blood gases in acute respiratory failure. BMJ 1970;2:452–5.
- Campbell EJM. The management of acute respiratory failure in chronic bronchitisand emphysema. Am Rev Respir Dis 1967;96:26–639.
- Thomson AJ, Webb DJ, Maxwell SR, et al. Oxygen therapy in acute medical care. BMJ 2002;324:1406–7.
- Aubier M, Murciano D, Milic Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980;122:747–54.
- Oxygen Therapy and Pulmonary Oxygen Toxicity .Fishman’s pulmonary disease and disorders.5th edition
COOSMIC SLEEP LAB
COOSMIC SLEEP LAB PROVIDE ALL TYPE OF SOLUTION TO YOU SLEEP PROBLEMS IN GENERAL AND SLEEP APNEA IN PARTICULAR IN GUWAHATI AND NORTH EAST REGION OF INDIA, MOSTLY FOCUS ON HOME BASED SLEEP STUDY TEST
CONTACT
08811095389
email- coosmicsleeplab@gmail.com
welcome and disclaimer
DISCLAIMER:
Information provided here is for medical education only. It is not intended as and does not substitute for medical advice. If you are a patient, please see your doctor for evaluation of your individual case. The web site should not be used as a substitute for competent medical advice from a licensed physician. By accessing the web site, the visitors acknowledge that there is no physician-patient relationship between them and the author. Under no circumstances will the author be liable to you for any direct or indirect damages arising in connection with use of this website.
The appearance of external hyperlinks to other websites does not constitute endorsement. The author does not verify, endorse, or take responsibility for the accuracy, currency, completeness or quality of the content contained in these sites.


